-
The government will negotiate new prices for the commonly prescribed drugs, but the cuts won't take effect until 2026. In the meantime, drugmakers are fighting the negotiations with lawsuits.
-
Supreme Court's decision to review the controversial bankruptcy deal involving the maker of Oxycontin means the settlement will remain on hold at least through December.
-
Overdose deaths from fentanyl and other opioids have surged but medications that could save thousands of lives "are sitting on the shelf unused," according to new research.
-
As money is funneled to states, opioid councils wield significant power in determining how it gets spent. They face concerns about conflicts of interest and lack of representation by affected groups.
-
At least nine bills introduced in Congress take aim at pharmacy benefit managers, the powerful middlemen that channel prescription drugs to patients. Here's what the fuss is all about.
-
All told, drugmakers and distributors will pay over $50 billion to communities harmed by opioids. An investigation finds that only a dozen states are letting the public see how they use the money.
-
A total of 295 types of drugs — everything from sedatives to children's flu medicine — were in short supply in 2022, according to a new report from the U.S. Senate Committee on Homeland Security.
-
The fentanyl crisis is hitting young people hard, and the highest death rates are in Native American communities. The Cherokee Nation is working to help young families recover.
-
The Food and Drug Administration has new tools to hold drug companies accountable for promises they make about medications. But the agency has yet to show its hand in using this new power.
-
It costs $5 a month and includes generic medications for more than 80 common health conditions.